Kura Oncology Inc (NASDAQ:KURA) Expected to Announce Earnings of -$0.43 Per Share

Equities research analysts expect that Kura Oncology Inc (NASDAQ:KURA) will post earnings of ($0.43) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Kura Oncology’s earnings, with the highest EPS estimate coming in at ($0.40) and the lowest estimate coming in at ($0.48). Kura Oncology reported earnings per share of ($0.45) in the same quarter last year, which would suggest a positive year over year growth rate of 4.4%. The business is scheduled to issue its next quarterly earnings results on Monday, August 5th.

According to Zacks, analysts expect that Kura Oncology will report full-year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($1.89) to ($1.58). For the next year, analysts anticipate that the business will post earnings of ($2.02) per share, with EPS estimates ranging from ($2.50) to ($1.66). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Kura Oncology.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, May 7th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08.

KURA has been the topic of a number of recent analyst reports. HC Wainwright set a $31.00 target price on Kura Oncology and gave the stock a “buy” rating in a report on Wednesday, May 8th. Zacks Investment Research raised Kura Oncology from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a report on Wednesday, May 8th. ValuEngine raised Kura Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, March 27th. Oppenheimer reissued a “buy” rating on shares of Kura Oncology in a report on Tuesday, March 19th. Finally, Citigroup boosted their target price on Kura Oncology from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, May 24th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $28.00.

KURA stock opened at $19.55 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.80 and a quick ratio of 13.80. The firm has a market cap of $732.00 million, a price-to-earnings ratio of -11.37 and a beta of 2.46. Kura Oncology has a 1-year low of $10.20 and a 1-year high of $22.00. The business’s 50 day simple moving average is $17.16.

Hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers grew its position in shares of Kura Oncology by 59.1% during the fourth quarter. Rhumbline Advisers now owns 37,118 shares of the company’s stock worth $521,000 after acquiring an additional 13,781 shares during the last quarter. California Public Employees Retirement System grew its position in shares of Kura Oncology by 228.6% during the fourth quarter. California Public Employees Retirement System now owns 153,300 shares of the company’s stock worth $2,152,000 after acquiring an additional 106,641 shares during the last quarter. BlackRock Inc. grew its position in shares of Kura Oncology by 0.6% during the fourth quarter. BlackRock Inc. now owns 2,409,979 shares of the company’s stock worth $33,836,000 after acquiring an additional 13,842 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Kura Oncology by 8.2% during the fourth quarter. Bank of New York Mellon Corp now owns 121,473 shares of the company’s stock worth $1,706,000 after acquiring an additional 9,218 shares during the last quarter. Finally, Citigroup Inc. grew its position in shares of Kura Oncology by 129.8% during the fourth quarter. Citigroup Inc. now owns 111,977 shares of the company’s stock worth $1,572,000 after acquiring an additional 63,241 shares during the last quarter. 83.93% of the stock is currently owned by hedge funds and other institutional investors.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Featured Article: Trade Deficit

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.